Compare Stocks

Date Range: 

 Universe PharmaceuticalsViridian TherapeuticsOxford BioDynamicsPediapharmReNeuron Group
SymbolNYSE:UPCNASDAQ:VRDNLON:OBDCVE:PDPLON:RENE
Price Information
Current Price$2.97$16.24GBX 57.60C$0.30GBX 117.84
52 Week RangeN/ABuyN/AN/AN/A
MarketRank™
Overall Score0.01.50.50.50.6
Analysis Score0.03.50.00.00.0
Community Score0.03.32.42.53.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.60.00.00.0
Analyst Ratings
Consensus RecommendationN/ABuyN/AN/AN/A
Consensus Price TargetN/A$34.00N/AN/AN/A
% Upside from Price TargetN/A109.36% upsideN/AN/AN/A
Trade Information
Market Cap$64.16 million$62.53 million£53.96 millionC$66.36 million£66.25 million
BetaN/AN/AN/AN/AN/A
Average Volume2,513,84547,992137,868100,369243,535
Sales & Book Value
Annual RevenueN/A$1.05 million£456,000.00C$11.16 million£112,000.00
Price / SalesN/A60.44116.925.95598.29
CashflowN/AN/AGBX 12.25 per shareC$0.01 per shareGBX 30.95 per share
Price / CashN/AN/A4.7023.083.81
Book ValueN/A($15.55) per shareGBX 14.70 per shareC($0.01) per shareGBX 20.80 per share
Price / BookN/A-1.040.04-23.080.06
Profitability
Net IncomeN/A$-110,710,000.00N/AN/AN/A
EPSN/A($11.49)GBX (4.70)C($0.07)GBX (45.90)
Trailing P/E Ratio0.00N/AN/AN/AN/A
Forward P/E RatioN/A
P/E GrowthN/AN/AN/A150.00N/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/A-1,934.14%N/AN/AN/A
Return on Assets (ROA)N/A-64.01%N/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AC$0.14N/A
Dividend YieldN/AN/AN/A46.67%N/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/A N/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.20%3.98%186.87%11.98%
Current RatioN/A7.39%10.01%1.12%1.77%
Quick RatioN/A7.39%9.59%0.71%1.77%
Ownership Information
Institutional Ownership Percentage0.38%N/AN/AN/AN/A
Insider Ownership PercentageN/A8.70%N/AN/AN/A
Miscellaneous
EmployeesN/A2637N/A62
Shares Outstanding21.75 million3.91 million92.56 million221.19 million56.86 million
Next Earnings DateN/A8/4/2021 (Estimated)6/15/2021 (Estimated)N/A7/19/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
ReNeuron Group plc - Update for hRPC therapy candidate studyReNeuron Group plc - Update for hRPC therapy candidate study
proactiveinvestors.co.uk - June 9 at 12:33 PM
ReNeuron now expects hRPC study data in fourth quarterReNeuron now expects hRPC study data in fourth quarter
proactiveinvestors.co.uk - June 9 at 12:33 PM
Update for hRPC therapy candidate studyUpdate for hRPC therapy candidate study
sharesmagazine.co.uk - June 9 at 7:33 AM
ReNeuron Group (LON:RENE) Stock Passes Below 50-Day Moving Average of $134.33ReNeuron Group (LON:RENE) Stock Passes Below 50-Day Moving Average of $134.33
americanbankingnews.com - May 27 at 3:00 AM
ReNeuron hires new chief scientific officer as it grows pipelineReNeuron hires new chief scientific officer as it grows pipeline
shareprices.com - May 20 at 8:21 AM
ReNeuron appoints new chief scientific officerReNeuron appoints new chief scientific officer
proactiveinvestors.co.uk - May 20 at 3:21 AM
ReNeuron Group plc - Appointment of Chief Scientific OfficerReNeuron Group plc - Appointment of Chief Scientific Officer
proactiveinvestors.co.uk - May 20 at 3:21 AM
ReNeuron signs new collaboration agreementsReNeuron signs new collaboration agreements
sharecast.com - March 19 at 1:02 PM
AIM WINNERS & LOSERS: Futura Medical up on EU medical device clearanceAIM WINNERS & LOSERS: Futura Medical up on EU medical device clearance
lse.co.uk - March 19 at 8:00 AM
ReNeuron inks commercial collaboration deals for exosome platformReNeuron inks commercial collaboration deals for exosome platform
lse.co.uk - March 19 at 8:00 AM
ReNeuron unveils new collaborations, data findings on exosome technology platformReNeuron unveils new collaborations, data findings on exosome technology platform
proactiveinvestors.co.uk - March 19 at 8:00 AM
ReNeuron jumps after unveiling new collaborations on exosome technology platformReNeuron jumps after unveiling new collaborations on exosome technology platform
proactiveinvestors.co.uk - March 19 at 8:00 AM
ReNeuron begins search for new chief financial officerReNeuron begins search for new chief financial officer
proactiveinvestors.co.uk - March 12 at 8:52 PM
ReNeuron Group plc - Appointment of Joint BrokerReNeuron Group plc - Appointment of Joint Broker
proactiveinvestors.co.uk - February 25 at 3:59 AM
Exosome Diagnostic and Therapeutics Market 2021 to 2025 Growth Factors, Market Characteristics, Opportunities By Type Analysis and ForecastExosome Diagnostic and Therapeutics Market 2021 to 2025 Growth Factors, Market Characteristics, Opportunities By Type Analysis and Forecast
marketwatch.com - February 16 at 7:00 AM
ReNeuron Group plc - Total Voting RightsReNeuron Group plc - Total Voting Rights
proactiveinvestors.co.uk - February 1 at 12:24 PM
Clinical update - Treatment of first patient cohort completed in Phase 2a extension of retinal disease studyClinical update - Treatment of first patient cohort completed in Phase 2a extension of retinal disease study
pharmiweb.com - January 15 at 4:34 PM
Notification of Allowance granted for US patentNotification of Allowance granted for US patent
pharmiweb.com - December 17 at 3:06 PM
Director Deals - Reneuron Group PLC (RENE)Director Deals - Reneuron Group PLC (RENE)
stockmarketwire.com - December 16 at 11:02 PM
Reneuron Share News (RENE)Reneuron Share News (RENE)
lse.co.uk - December 11 at 2:32 PM
UK TRADING UPDATE SUMMARY: ReNeuron Plans Fundraise To Support StudyUK TRADING UPDATE SUMMARY: ReNeuron Plans Fundraise To Support Study
lse.co.uk - November 25 at 10:19 PM
ReNeuron Group plc - Interim ResultsReNeuron Group plc - Interim Results
proactiveinvestors.com - November 25 at 10:19 PM
ReNeuron Group plc - Second Price Monitoring ExtnReNeuron Group plc - Second Price Monitoring Extn
proactiveinvestors.co.uk - November 24 at 6:04 PM
ReNeuron raising up to £15mln to fund two key R&D programmesReNeuron raising up to £15mln to fund two key R&D programmes
proactiveinvestors.co.uk - November 24 at 8:03 AM
Stem Cells Market Size to Rake USD 17.79 Billion by 2027Stem Cells Market Size to Rake USD 17.79 Billion by 2027
arnnet.com.au - October 29 at 7:56 AM
DateCompanyBrokerageAction
1/25/2021Viridian TherapeuticsLADENBURG THALM/SH SHInitiated Coverage
1/20/2021Viridian TherapeuticsJefferies Financial GroupBoost Price Target
6/16/2020Oxford BioDynamicsShore CapitalReiterated Rating
(Data available from 6/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.